#1 Clinical Trials Search in Europe

Bi 3032950

BI 3032950 is an investigational drug currently being studied in clinical trials for its potential in treating ulcerative colitis and its safety profile in healthy individuals. These trials aim to evaluate the drug’s effectiveness, safety, and how it behaves in the body when administered through different methods, including intravenous infusion and subcutaneous injection.

Table of Contents

What is BI 3032950?

BI 3032950 is a new drug currently being studied for its potential in treating ulcerative colitis, a chronic inflammatory bowel disease. This medication is still in the research phase and is not yet approved for general use.[1] Scientists are conducting various studies to understand how well it works and how safe it is for patients.

How is BI 3032950 Administered?

Based on the ongoing clinical trials, BI 3032950 can be administered in two ways:

  1. Intravenous (IV) infusion: The drug is given directly into a vein. This method is being used in the initial phase of treatment.[2]
  2. Subcutaneous (SC) injection: The drug is injected under the skin. This method is being tested for long-term maintenance treatment.[2]

The specific dosing schedule and duration of treatment are still being determined through clinical trials.

What Conditions Does BI 3032950 Treat?

The primary focus of BI 3032950 research is on treating ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum. Symptoms can include:

  • Diarrhea, often with blood or pus
  • Abdominal pain and cramping
  • Rectal pain and bleeding
  • Urgency to have a bowel movement
  • Weight loss
  • Fatigue

BI 3032950 is being studied specifically for patients with moderate to severe ulcerative colitis who have not responded well to previous treatments or have had to stop other treatments.[2]

Clinical Trials and Research

Several clinical trials are currently underway to evaluate BI 3032950:

  1. Safety and Tolerability Study in Healthy Individuals: This study aims to test how well repeated doses of BI 3032950 are tolerated in healthy people. It involves both men and women who are not of childbearing potential.[1]
  2. Ulcerative Colitis Treatment Study: This is a Phase IIa trial specifically for patients with moderate to severe ulcerative colitis. The study has two parts:
    • Part A: Participants receive BI 3032950 as an IV infusion every 4 weeks for 12 weeks.
    • Part B: Participants receive BI 3032950 as a subcutaneous injection every 4 weeks for up to 2 years.
    Doctors will regularly assess the signs and symptoms of ulcerative colitis, including blood tests, stool samples, and endoscopies.[2]
  3. Single Dose Study in Healthy Men: This study tests different single doses of BI 3032950 in healthy male subjects, administered either intravenously or subcutaneously.[3]

Safety and Side Effects

As BI 3032950 is still in the research phase, its full safety profile is not yet established. The ongoing clinical trials are designed to carefully monitor and assess any potential side effects or adverse events. Some key points about safety:

  • Researchers are closely tracking the occurrence of any treatment-emergent adverse events (side effects that appear or worsen after starting the medication).[1][2][3]
  • Special attention is being paid to adverse events that doctors consider to be related to the drug.[1][3]
  • The studies include regular health check-ups and monitoring of participants to ensure their safety throughout the trial period.[2]

It’s important to note that all new medications can have potential risks and side effects. The purpose of these clinical trials is to identify and understand these risks before the drug becomes widely available.

Potential Benefits

While it’s too early to draw definitive conclusions, researchers are hopeful that BI 3032950 could offer several benefits for patients with ulcerative colitis:

  • Clinical remission: The primary goal is to achieve a significant reduction in ulcerative colitis symptoms, potentially leading to remission. This is measured using the modified Mayo Score, which assesses stool frequency, rectal bleeding, and the appearance of the colon during an endoscopy.[2]
  • Endoscopic improvement: Researchers are looking for signs that the medication helps heal the lining of the colon, which can be observed during an endoscopy.[2]
  • Reduced symptoms: The studies are tracking improvements in specific symptoms such as stool frequency and rectal bleeding.[2]
  • Long-term management: If successful, BI 3032950 could provide a new option for long-term management of ulcerative colitis, particularly for patients who haven’t responded well to other treatments.[2]

It’s important to remember that BI 3032950 is still in the experimental stage. More research is needed to fully understand its effectiveness and safety profile. Patients with ulcerative colitis should continue to work closely with their healthcare providers to manage their condition using currently approved treatments.

Aspect Details
Drug Name BI 3032950
Conditions Studied Ulcerative Colitis, Safety in Healthy Individuals
Administration Methods Intravenous Infusion, Subcutaneous Injection
Study Objectives Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy in Ulcerative Colitis
Study Designs Single-blind, Randomized, Placebo-controlled, Open-label
Key Outcome Measures Adverse Events, Drug Concentration in Blood, Clinical Remission, Endoscopic Improvement
Study Duration Varies from weeks to up to 2 years

FAQ

  • What is BI 3032950? BI 3032950 is an investigational drug being studied for its potential in treating ulcerative colitis and its safety in healthy individuals. It is administered either intravenously (into a vein) or subcutaneously (under the skin).
  • What conditions are being studied with BI 3032950? The main condition being studied with BI 3032950 is ulcerative colitis, a type of inflammatory bowel disease. Additionally, the drug is being tested in healthy individuals to assess its safety and how it behaves in the body.
  • How is BI 3032950 administered in the clinical trials? In the clinical trials, BI 3032950 is administered in different ways depending on the study. It can be given as an intravenous infusion (into a vein) or as a subcutaneous injection (under the skin). The method and frequency of administration may vary between studies.
  • What are the main objectives of the BI 3032950 clinical trials? The main objectives of the clinical trials include investigating the safety and tolerability of BI 3032950, studying how the drug behaves in the body (pharmacokinetics), and evaluating its effectiveness in treating ulcerative colitis symptoms.
  • How long do the clinical trials for BI 3032950 last? The duration of the clinical trials varies. Some studies last for a few weeks, while others, particularly those involving ulcerative colitis patients, can last up to 2 years. The exact duration depends on the specific trial design and objectives.

Ongoing Clinical Trials on Bi 3032950

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • Ulcerative Colitis: A type of inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Intravenous Infusion: A method of delivering medication directly into a vein using a needle or catheter.
  • Subcutaneous Injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Endoscopy: A medical procedure that uses a long, thin tube with a camera to look inside the body, often used to examine the digestive tract.
  • Modified Mayo Score: A scoring system used to assess the severity of ulcerative colitis, considering factors like stool frequency, rectal bleeding, and endoscopic findings.
  • Clinical Remission: A state in which the signs and symptoms of a disease are reduced or gone, often used as a treatment goal in ulcerative colitis.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it's related to the treatment being studied.
  • Placebo: An inactive substance that looks like the drug being tested but has no medical effect, used as a control in clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT05985200
  2. https://clinicaltrials.gov/study/NCT06636656
  3. https://clinicaltrials.gov/study/NCT05518708